AP3S2

Across TCGA pan-cancer cohorts, AP3S2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AP3S2 data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher AP3S2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AP3S2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

UCEC, CCRCC, and LUAD are the cancer types where AP3S2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.854	1.000	.012	8	view →
CCRCC	OS	Median	All	1.000	0.638	.028	6	view →
LUAD	OS	Median	II,III,IV	0.395	0.914	.026	6	view →
LSCC	OS	Median	III,IV	0.766	1.000	.028	4	view →
HNSC	DFS	Median	IV	0.507	1.000	.035	3	view →
PDAC	DFS	Median	All	0.740	0.433	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AP3S2–UCEC (DFS)

Open the UCEC breakdown →